Brief: Quest Pharmatech Unit Sign License Agreement With Stanford University
03/01/2018 14:32
Jan 3 (Reuters) - Quest Pharmatech Inc QPT.V :
* QUEST PHARMATECH- UNIT SIGN EXCLUSIVE LICENSE AGREEMENT
WITH
STANFORD UNIVERSITY TO DEVELOP & COMMERCIALIZE PATENTED EGF
WOUND HEALING TECHNOLOGY
Source text for Eikon: ID:nCNWSJzHRa
Further company coverage: QPT.V
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Quest PharmaTech
See all newsBrief: Quest Pharmatech Announces Change Of Chief Executive Officer
Brief: Quest Pharmatech Provides Product Development Update
Brief: Quest PharmaTech Clarifies Agreement in Principle with OQP Bio
Brief: Quest Pharmatech Provides Corporate Update
Brief: Quest PharmaTech Announces Sale Of Bioceltran Investment And Return Of Photodynamic Therapy Technology License